ArticlePloS one2025
The relationship between serum eosinophil peroxidase and major basic protein levels in relation to severity and response to H1 antihistamines in chronic spontaneous Urticaria.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn chronic spontaneous urticaria (CSU), the significance of serum Eosinophil Peroxidase (EPO) and Major Basic Protein (MBP) levels as indicators of disease severity and response to antihistamine treatment is currently inadequately understood. This study explores the correlation between serum EPO and MBP levels, the severity of the disease, and the efficacy of antihistamines in patients with CSU.
methodsA cross-sectional study involved 120 CSU patients alongside 30 healthy controls. In addition, a cohort study targeted 60 patients diagnosed with severe CSU, defined by a Urticaria Activity Score over 7 days (UAS7 ≥ 28). Initially, these patients received a dose of 20 mg of bilastine, which could be increased to a maximum of 80 mg depending on the results of the Urticaria Control Test (UCT) conducted on days 15, 30, and 60. Baseline serum concentrations of EPO and MBP were assessed for all participants, with follow-up measurements conducted after two months for those with severe CSU utilizing an ELISA kit..
resultsSerum EPO concentration in the severe CSU group was similar to that in the non-severe group (P = 0.33) and was higher than that in the healthy control group (P < 0.001). Serum MBP concentrations did not differ among these three groups (P = 0.19). Serum EPO and MBP concentrations did not correlate with UAS7 and UCT. They did not differ among antihistamine response groups in the severe CSU group (P > 0.05) and decreased after 2 months of antihistamine treatment (P < 0.05).
conclusionsSerum EPO and MBP levels are neither biomarkers predicting CSU severity nor factors predicting response to antihistamine in the severe group. This lack of association may help explain why treatments targeting eosinophil proliferation and chemotaxis have not been successful in clinical trials for patients with antihistamine-refractory CSU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.